{"id":3107,"date":"2017-01-17T08:37:09","date_gmt":"2017-01-16T23:07:09","guid":{"rendered":"http:\/\/hepatitissa.asn.au\/blog\/?p=328"},"modified":"2024-06-03T20:58:34","modified_gmt":"2024-06-03T11:28:34","slug":"new-improved-hep-b-medicine-considered-for-pbs","status":"publish","type":"post","link":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/","title":{"rendered":"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme"},"content":{"rendered":"\n

As Australians with hepatitis C are being cured at unprecedented rates, there is promise of a better medicine for those living with chronic hepatitis B who need treatment.<\/p>\n\n\n\n

The Pharmaceutical Benefits Advisory Committee (PBAC) will, in March, consider for recommendation, a new medicine which promises the same efficacy as current drugs but with less toxic side effects.<\/p>\n\n\n\n

The current medicine, tenofovir disoproxil fumarate (TDF), is effective in suppressing the hepatitis B virus but is also linked to bone density loss and renal dysfunction in some patients. This is due to the high level of tenofovir circulating in the body.<\/p>\n\n\n\n

Less\u00a0toxicity<\/strong><\/h3>\n\n\n\n

TDF – also known as Viread – is a tenofovir prodrug, an inactive compound which converts to tenofovir in the body, after it is ingested.<\/p>\n\n\n\n

Another new prodrug (TAF or Vemlidy) is now available which can achieve the same level of virus suppression with one-tenth the dosage. This results in a lower level of tenofovir circulating the the body, thus reducing the damaging effect on bone density and renal function.<\/p>\n\n\n\n

The new medicine – tenofovir alafenamide (TAF) has more stable structure which allows a more efficient delivery of tenofovir to the liver cells. The treatment is given as a once daily tablet. Each TAF tablet is 25 mg compared to 245 mg for TDF.<\/p>\n\n\n\n

About 213,000 Australians live with hepatitis B and about 380 die each year from hepatitis B related causes. It is a leading cause of liver cancer, the cancer with highest rate of increase in Australia.<\/p>\n\n\n\n

Not everyone with chronic hepatitis B needs treatment but experts have estimated that at any given time, 15 per cent will require treatment. If the condition is left unmanaged, one in four people with chronic hepatitis B will face adverse outcomes such as liver failure or liver cancer.<\/p>\n\n\n\n

A better medicine with less toxic side effect would encourage more people who need hepatitis B treatment to take it up.<\/p><\/blockquote><\/figure>\n\n\n\n

Treatment uptake among Australians living with chronic hepatitis B is lower than the recommended 15 per cent. South Australia’s treatment rate at 2.9 per cent, is significantly below the national average of 5.3 per cent.<\/p>\n\n\n\n

Saving money and lives<\/b><\/h3>\n\n\n\n

A recent study<\/a> by specialists from the University of Flinders show that increasing the treatment rate from 2.9 per cent to 10 per cent would save the state almost $14 million over the next 10 years, and almost $23.8 million if treatment uptake was increased to 15 per cent.<\/p>\n\n\n\n

Increasing the treatment rate from 2.9 to 15 per cent would also halve the number of liver cancer cases over the next 10 years. (See issue #72 of Hepatitis SA Community News<\/a> for more.)<\/p>\n\n\n\n

A better medicine with less toxic side effect would encourage more people who need hepatitis B treatment to take it up.<\/p>\n\n\n\n

That will provide a better quality of life and better outcomes for Australians living with chronic hepatitis B. In the long run it will also reduce the burden on the health budget.<\/p>\n\n\n\n

The US Food and Drug Administration (FDA) cleared TAF for use with hepatitis B<\/a> in November 2016, and the European Commission has authorised it for marketing in the EU<\/a>. It is not unreasonable to hope that this new treatment will be made available soon in Australia on the Pharmaceutical Benefits Scheme.<\/p>\n\n\n\n

Update (27 April 2017<\/strong>) – The PBAC has recommended listing tenofovir alafenamide 25 mg tablets for treatment of chronic hepatitis B at its March 2017 meeting. <\/em><\/p>\n\n\n\n

More information:
Medscape<\/a> | Journal Watch<\/a> | PBAC March agenda<\/a> | PBAC Recommendation<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

As Australians with hepatitis C are being cured at unprecedented rates, there is promise of a better medicine for those living with chronic hepatitis B who need treatment. The Pharmaceutical Benefits Advisory …<\/p>\n","protected":false},"author":2,"featured_media":3063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_FSMCFIC_featured_image_caption":"","_FSMCFIC_featured_image_nocaption":"","_FSMCFIC_featured_image_hide":"","footnotes":""},"categories":[11,13],"tags":[34,39],"issue":[],"ppma_author":[56],"class_list":["post-3107","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policies-research","category-living-with-hepatitis","tag-hepatitis-b","tag-treatment"],"acf":[],"yoast_head":"\nNew Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme | HepSA Community News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme | HepSA Community News\" \/>\n<meta property=\"og:description\" content=\"As Australians with hepatitis C are being cured at unprecedented rates, there is promise of a better medicine for those living with chronic hepatitis B who need treatment. The Pharmaceutical Benefits Advisory …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\" \/>\n<meta property=\"og:site_name\" content=\"HepSA Community News\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/HepatitisSA\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-16T23:07:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-03T11:28:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"997\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Cecilia Lim\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hep_sa\" \/>\n<meta name=\"twitter:site\" content=\"@hep_sa\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cecilia Lim\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\"},\"author\":{\"name\":\"Cecilia Lim\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/person\/efdf385408c3eb224631b1314de31e49\"},\"headline\":\"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme\",\"datePublished\":\"2017-01-16T23:07:09+00:00\",\"dateModified\":\"2024-06-03T11:28:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\"},\"wordCount\":591,\"commentCount\":4,\"publisher\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#organization\"},\"image\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg\",\"keywords\":[\"Hepatitis B\",\"treatment\"],\"articleSection\":[\"Policies & Research\",\"Living with Hepatitis\"],\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\",\"url\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\",\"name\":\"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme | HepSA Community News\",\"isPartOf\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg\",\"datePublished\":\"2017-01-16T23:07:09+00:00\",\"dateModified\":\"2024-06-03T11:28:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#breadcrumb\"},\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage\",\"url\":\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg\",\"contentUrl\":\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg\",\"width\":2048,\"height\":997},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hepatitissa.asn.au\/communitynews\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#website\",\"url\":\"https:\/\/hepatitissa.asn.au\/communitynews\/\",\"name\":\"HepSA Community News\",\"description\":\"Hepatitis news and views from South Australia\",\"publisher\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hepatitissa.asn.au\/communitynews\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-AU\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#organization\",\"name\":\"Hepatitis SA\",\"url\":\"https:\/\/hepatitissa.asn.au\/communitynews\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2024\/03\/HepSA_rgb.png\",\"contentUrl\":\"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2024\/03\/HepSA_rgb.png\",\"width\":2025,\"height\":955,\"caption\":\"Hepatitis SA\"},\"image\":{\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/HepatitisSA\",\"https:\/\/x.com\/hep_sa\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/person\/efdf385408c3eb224631b1314de31e49\",\"name\":\"Cecilia Lim\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=gafa69379198950dc40495a8dfb125bd3\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=g\",\"caption\":\"Cecilia Lim\"},\"url\":\"https:\/\/hepatitissa.asn.au\/communitynews\/author\/cecilia-lim\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme | HepSA Community News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/","og_locale":"en_US","og_type":"article","og_title":"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme | HepSA Community News","og_description":"As Australians with hepatitis C are being cured at unprecedented rates, there is promise of a better medicine for those living with chronic hepatitis B who need treatment. The Pharmaceutical Benefits Advisory …","og_url":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/","og_site_name":"HepSA Community News","article_publisher":"https:\/\/www.facebook.com\/HepatitisSA","article_published_time":"2017-01-16T23:07:09+00:00","article_modified_time":"2024-06-03T11:28:34+00:00","og_image":[{"width":2048,"height":997,"url":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg","type":"image\/jpeg"}],"author":"Cecilia Lim","twitter_card":"summary_large_image","twitter_creator":"@hep_sa","twitter_site":"@hep_sa","twitter_misc":{"Written by":"Cecilia Lim","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#article","isPartOf":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/"},"author":{"name":"Cecilia Lim","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/person\/efdf385408c3eb224631b1314de31e49"},"headline":"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme","datePublished":"2017-01-16T23:07:09+00:00","dateModified":"2024-06-03T11:28:34+00:00","mainEntityOfPage":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/"},"wordCount":591,"commentCount":4,"publisher":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#organization"},"image":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage"},"thumbnailUrl":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg","keywords":["Hepatitis B","treatment"],"articleSection":["Policies & Research","Living with Hepatitis"],"inLanguage":"en-AU","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/","url":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/","name":"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme | HepSA Community News","isPartOf":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage"},"image":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage"},"thumbnailUrl":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg","datePublished":"2017-01-16T23:07:09+00:00","dateModified":"2024-06-03T11:28:34+00:00","breadcrumb":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#breadcrumb"},"inLanguage":"en-AU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/"]}]},{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#primaryimage","url":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg","contentUrl":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2017\/01\/Vemlidy-lookalike-web-scaled.jpg","width":2048,"height":997},{"@type":"BreadcrumbList","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/2017\/01\/new-improved-hep-b-medicine-considered-for-pbs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hepatitissa.asn.au\/communitynews\/"},{"@type":"ListItem","position":2,"name":"New Improved Hepatitis B Medicine to be Considered for Pharmaceutical Benefits Scheme"}]},{"@type":"WebSite","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#website","url":"https:\/\/hepatitissa.asn.au\/communitynews\/","name":"HepSA Community News","description":"Hepatitis news and views from South Australia","publisher":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hepatitissa.asn.au\/communitynews\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-AU"},{"@type":"Organization","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#organization","name":"Hepatitis SA","url":"https:\/\/hepatitissa.asn.au\/communitynews\/","logo":{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/logo\/image\/","url":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2024\/03\/HepSA_rgb.png","contentUrl":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-content\/uploads\/2024\/03\/HepSA_rgb.png","width":2025,"height":955,"caption":"Hepatitis SA"},"image":{"@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/HepatitisSA","https:\/\/x.com\/hep_sa"]},{"@type":"Person","@id":"https:\/\/hepatitissa.asn.au\/communitynews\/#\/schema\/person\/efdf385408c3eb224631b1314de31e49","name":"Cecilia Lim","image":{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=gafa69379198950dc40495a8dfb125bd3","url":"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=g","caption":"Cecilia Lim"},"url":"https:\/\/hepatitissa.asn.au\/communitynews\/author\/cecilia-lim\/"}]}},"authors":[{"term_id":56,"user_id":2,"is_guest":0,"slug":"cecilia-lim","display_name":"Cecilia Lim","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/0791a46acf6147a34520719a3f0680a122d9e93c36d981f734e9d7d3d5a24b50?s=96&d=mm&r=g","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/posts\/3107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/comments?post=3107"}],"version-history":[{"count":5,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/posts\/3107\/revisions"}],"predecessor-version":[{"id":4266,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/posts\/3107\/revisions\/4266"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/media\/3063"}],"wp:attachment":[{"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/media?parent=3107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/categories?post=3107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/tags?post=3107"},{"taxonomy":"issue","embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/issue?post=3107"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/hepatitissa.asn.au\/communitynews\/wp-json\/wp\/v2\/ppma_author?post=3107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}